Phase II trial of vindesine in patients with germ-cell tumors

T. F. Reynolds, D. Vugrin, E. Cvitkovic, Richard J. Gralla, C. W. Young, R. B. Golbey

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Vindesine, a vinblastine derivative, began clinical trial in 1975. It has an antitumor spectrum in animals similar to that of vincristine, but with less neurotoxicity. Phase I trials of vindesine at Memorial Sloan-Kettering Cancer Center explored both a weekly and a daily x 5 dose schedule. A dose of 1.3 mg/m 2/day x 5-7 days every 3 weeks was well-tolerated. There were 2 measurable remissions in 6 heavily pretreated patients with testicular cancer. A phase II trial of vindesine in patients with germ-cell tumors who had failed to respond to conventional chemotherapy was begun in January 1977 and this is a report of the results.

Original languageEnglish (US)
Pages (from-to)1399-1401
Number of pages3
JournalCancer Treatment Reports
Volume63
Issue number8
StatePublished - 1979
Externally publishedYes

Fingerprint

Vindesine
Germ Cell and Embryonal Neoplasms
Vinblastine
Testicular Neoplasms
Vincristine
Appointments and Schedules
Clinical Trials
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Reynolds, T. F., Vugrin, D., Cvitkovic, E., Gralla, R. J., Young, C. W., & Golbey, R. B. (1979). Phase II trial of vindesine in patients with germ-cell tumors. Cancer Treatment Reports, 63(8), 1399-1401.

Phase II trial of vindesine in patients with germ-cell tumors. / Reynolds, T. F.; Vugrin, D.; Cvitkovic, E.; Gralla, Richard J.; Young, C. W.; Golbey, R. B.

In: Cancer Treatment Reports, Vol. 63, No. 8, 1979, p. 1399-1401.

Research output: Contribution to journalArticle

Reynolds, TF, Vugrin, D, Cvitkovic, E, Gralla, RJ, Young, CW & Golbey, RB 1979, 'Phase II trial of vindesine in patients with germ-cell tumors', Cancer Treatment Reports, vol. 63, no. 8, pp. 1399-1401.
Reynolds TF, Vugrin D, Cvitkovic E, Gralla RJ, Young CW, Golbey RB. Phase II trial of vindesine in patients with germ-cell tumors. Cancer Treatment Reports. 1979;63(8):1399-1401.
Reynolds, T. F. ; Vugrin, D. ; Cvitkovic, E. ; Gralla, Richard J. ; Young, C. W. ; Golbey, R. B. / Phase II trial of vindesine in patients with germ-cell tumors. In: Cancer Treatment Reports. 1979 ; Vol. 63, No. 8. pp. 1399-1401.
@article{08666103ccba44278e66d4c459754bbd,
title = "Phase II trial of vindesine in patients with germ-cell tumors",
abstract = "Vindesine, a vinblastine derivative, began clinical trial in 1975. It has an antitumor spectrum in animals similar to that of vincristine, but with less neurotoxicity. Phase I trials of vindesine at Memorial Sloan-Kettering Cancer Center explored both a weekly and a daily x 5 dose schedule. A dose of 1.3 mg/m 2/day x 5-7 days every 3 weeks was well-tolerated. There were 2 measurable remissions in 6 heavily pretreated patients with testicular cancer. A phase II trial of vindesine in patients with germ-cell tumors who had failed to respond to conventional chemotherapy was begun in January 1977 and this is a report of the results.",
author = "Reynolds, {T. F.} and D. Vugrin and E. Cvitkovic and Gralla, {Richard J.} and Young, {C. W.} and Golbey, {R. B.}",
year = "1979",
language = "English (US)",
volume = "63",
pages = "1399--1401",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Phase II trial of vindesine in patients with germ-cell tumors

AU - Reynolds, T. F.

AU - Vugrin, D.

AU - Cvitkovic, E.

AU - Gralla, Richard J.

AU - Young, C. W.

AU - Golbey, R. B.

PY - 1979

Y1 - 1979

N2 - Vindesine, a vinblastine derivative, began clinical trial in 1975. It has an antitumor spectrum in animals similar to that of vincristine, but with less neurotoxicity. Phase I trials of vindesine at Memorial Sloan-Kettering Cancer Center explored both a weekly and a daily x 5 dose schedule. A dose of 1.3 mg/m 2/day x 5-7 days every 3 weeks was well-tolerated. There were 2 measurable remissions in 6 heavily pretreated patients with testicular cancer. A phase II trial of vindesine in patients with germ-cell tumors who had failed to respond to conventional chemotherapy was begun in January 1977 and this is a report of the results.

AB - Vindesine, a vinblastine derivative, began clinical trial in 1975. It has an antitumor spectrum in animals similar to that of vincristine, but with less neurotoxicity. Phase I trials of vindesine at Memorial Sloan-Kettering Cancer Center explored both a weekly and a daily x 5 dose schedule. A dose of 1.3 mg/m 2/day x 5-7 days every 3 weeks was well-tolerated. There were 2 measurable remissions in 6 heavily pretreated patients with testicular cancer. A phase II trial of vindesine in patients with germ-cell tumors who had failed to respond to conventional chemotherapy was begun in January 1977 and this is a report of the results.

UR - http://www.scopus.com/inward/record.url?scp=0018603492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018603492&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 1399

EP - 1401

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 8

ER -